|
Showing 1 - 3 of
3 matches in All Departments
The beginning of a new millennium is an ideal opportunity to look
back, to contemplate the present and to envisage what the future
might have to offer. This seems particularly appropriate for the
rapidly developing field of hepatology. Therefore, the aim of the
Falk Symposium 117, Hepatology 2000, held in Munich on 4-6 May
2000, was to offer state-of-the-art information on the most
important aspects of hepatology and to discuss the challenges of
the future. The presentations were given by experts in their
respective areas, providing an update and at the same time
incorporating the most recent developments. These proceedings, a
tour d'horizon of hepatology at the highest clinical and scientific
level, is dedicated to Gustav Paumgartner who has retired from his
duties as chairman of the Department of Medicine II at the
University of Munich- Grosshadern. The scientific organisers take
this opportunity to thank their academic teacher and to honour his
lifelong engagement and achievements in hepatology. This book is
cordially dedicated to him.
Bile acid research has attracted increasing attention from both
basic scientists and clinical hepatologists over the last decade.
Experimental studies have expanded our knowledge of the role of
bile acids in liver disease, and well-designed clinical trials have
documented beneficial effects of bile acid treatment for a number
of hepatobiliary diseases. Bile Acids in Liver Diseases, the
proceedings of an International Falk Workshop held in Munich,
January 1995, provides insights into current concepts in bile acid
chemistry, bile acid synthesis and metabolism, and transport of
bile acids across the hepatocyte. The role of bile acids in bile
formation, cholestasis and hepatotoxicity are discussed. Finally,
the book addresses experimental studies and hypotheses about the
putative mechanisms of action of ursodeoxycholic acid in
cholestatic liver diseases, and summarizes the clinical
applications of bile acid treatment on the basis of controlled
clinical trials.
Since the last International Bile Acid Meeting in Stockholm in
2004, bile acid research has continued to flourish and therapeutic
use of bile acids has attained a broader role. New insights have
been gained into the mechanisms responsible for maintenance of bile
acid homeostasis, and effects of bile acids on the cell signalling
pathways have been further elucidated. Knowledge of the genetic
basis of bile acid physiology has further increased. Therapy of
chronic cholestatic liver diseases with ursodeoxycholic acid and
new aspects of its chemopreventive properties continue to stimulate
basic and clinical research and contribute to the understanding of
underlying modes of action and to optimized treatment schedules.
Chapters reflect the recent progress in bile acid metabolism and
transport, nuclear receptor regulation and signaling by bile acids,
as well as mechanisms of bile acid-induced cellular injury...
|
|